A Community Approach to CAR-T Therapy for Patients with DLBCL or FL: Optimizing Referral, Coordination, and Care
Pre-Test

Questions marked with a * are required
100%
Contact Information
Which of the following is a patient-related barrier for treatment with chimeric antigen receptor (CAR) T-cell therapy?
Which of the following is a patient-related barrier for treatment with chimeric antigen receptor (CAR) T-cell therapy?
Which of the following patients with relapsed or refractory B-cell lymphoma would NOT be considered an appropriate candidate for referral to a CAR T-cell therapy center?
Which of the following patients with relapsed or refractory B-cell lymphoma would NOT be considered an appropriate candidate for referral to a CAR T-cell therapy center?
Susan is a 74-year-old female with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL). She was initially treated with front-line polatuzumab vedotin + R-CHP. Now eight months later, her disease is progressing. Susan has an ECOG performance status (PS) of 1. Which of the following treatment approaches would be most appropriate for Susan?
Susan is a 74-year-old female with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL). She was initially treated with front-line polatuzumab vedotin + R-CHP. Now eight months later, her disease is progressing. Susan has an ECOG performance status (PS) of 1. Which of the following treatment approaches would be most appropriate for Susan?
Brent is a 67-year-old man who has been referred for CAR-T therapy after receiving two prior lines of treatment for follicular lymphoma (FL). Currently, his disease has transformed to an aggressive large B-cell lymphoma subtype (CD19+, CD20-, BCL6+; Ki-67 72%) and he is experiencing explosive disease progression. What is the most appropriate course for Brent’s treatment at this time?
Brent is a 67-year-old man who has been referred for CAR-T therapy after receiving two prior lines of treatment for follicular lymphoma (FL). Currently, his disease has transformed to an aggressive large B-cell lymphoma subtype (CD19+, CD20-, BCL6+; Ki-67 72%) and he is experiencing explosive disease progression. What is the most appropriate course for Brent’s treatment at this time?
Powered by QuestionPro